RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

The mutation of K‐RAS represents one of the most frequent genetic alterations in cancer. Targeting of downstream effectors of RAS, including of MEK and ERK, has limited clinical success in cancer patients with K‐RAS mutations. The reduced sensitivity of K‐RAS‐mutated cells to certain MEK inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Xi, Tang, Zhiyu, Du, Rong, Yao, Zhan, Cheung, Shing‐Hu, Zhang, Xinwen, Wei, Jing, Zhao, Yuan, Du, Yunguang, Liu, Ye, Hu, Xiaoxia, Gong, Wenfeng, Liu, Yong, Gao, Yajuan, Huang, Zhiyue, Cao, Zongfu, Wei, Min, Zhou, Changyou, Wang, Lai, Rosen, Neal, Smith, Paul D., Luo, Lusong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400788/
https://www.ncbi.nlm.nih.gov/pubmed/32336014
http://dx.doi.org/10.1002/1878-0261.12698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400788/
https://www.ncbi.nlm.nih.gov/pubmed/32336014
http://dx.doi.org/10.1002/1878-0261.12698

Ejemplares similares